Antibiotherapy in children with atypical bacterial infections;Antibiothérapie des infections à bactéries atypiques de l'enfant

Archives de Pediatrie

Volumn 12, Issue SUPPL. 1, 2005, Pages

  Haas, H ^a  

^a CENTRE HOSPITALIER UNIVERSITAIRE DE NICE   (France)

Author keywords

Antibiotics, therapeutic use; Child; Mycobacterium infections, atypical

Indexed keywords

ANTIBIOTIC AGENT; AZITHROMYCIN; BETA LACTAM ANTIBIOTIC; CETHROMYCIN; CIPROFLOXACIN; CLARITHROMYCIN; DOXYCYCLINE; ERYTHROMYCIN; GARENOXACIN; GATIFLOXACIN; KETOLIDE; LEVOFLOXACIN; MACROLIDE; MOXIFLOXACIN; OFLOXACIN; PEFLOXACIN; PENICILLIN G; QUINOLINE DERIVED ANTIINFECTIVE AGENT; ROXITHROMYCIN; SPARFLOXACIN; TELITHROMYCIN; TROVAFLOXACIN;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC THERAPY; ASTHMA; BACTERIAL INFECTION; BACTERIAL PNEUMONIA; BACTERIAL VIRULENCE; CHILD; CHLAMYDOPHILA PNEUMONIAE; CLINICAL TRIAL; DISEASE EXACERBATION; DISEASE SEVERITY; HUMAN; IMMUNE DEFICIENCY; INFECTION COMPLICATION; LEGIONELLA PNEUMOPHILA; MYCOPLASMA PNEUMONIAE; OTITIS; PHARYNGITIS; PROGNOSIS; RECURRENT DISEASE; REVIEW; SICKLE CELL ANEMIA; UPPER RESPIRATORY TRACT INFECTION; WHEEZING;

EID: 18844461693     PISSN: 0929693X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0929-693X(05)80011-9     Document Type: Article

References (23)

1. Principi N., and Esposito S. Emerging role of Mycoplasma pneumoniae and Chlamydia pneumoniae in paediatric respiratory-tract infections Lancet Infect Dis 1 2001 334 344
2. Principi N., Esposito S., Blasi F., and Allegra L. Mowgli study group. Role of Mycoplasma pneumoniae and Chlamydia pneumoniae in children with community-acquired lower respiratory tract infections Clin Infect Dis 32 2001 1281 1289
3. La Scola B., and Maltezou H. Legionella and Q fever community acquired pneumonia in children Paediatr Respir Rev 5 suppl A 2004 171 177
4. Bégué P., and Castello-Herbreteau B. Infections graves chez l'enfant drépanocytaire: aspects cliniques et préventions Arch Pediatr 8 Suppl 4 2001 732s 741s
5. Waites K.B. New concepts of Mycoplasma pneumoniae infections in Children Pediatr Pulmonol 36 2003 267 278
6. Hammerschlag M.R. Pneumonia due to Chlamydia pneumoniae in children: epidemiology, diagnosis, and treatment Pediatr Pulmonol 36 2003 Nov 384 390
7. Schonwald S., Gunjaca M., Kolacny-Babic L., Car V., and Gosev M. Comparison of azithromycin and erythromycin in the treatment of atypical pneumonias J Antimicrob Chemother 25 Suppl A 1990 123 126
8. Manfredi R., Jannuzzi C., Mantero E., Longo L., Schiavone R., and Tempesta A. Clinical comparative study of azithromycin vs erythromycin in the treatment of acute respiratory tract infections in children J Chemother 4 1992 364 370
9. Ferwerda A., Moll H.A., and de Groot R. Respiratory tract infections by Mycoplasma pneumoniae in children: a review of diagnostic and therapeutic measures Eur J Pediatr 160 2001 483 491
10. Plouffe J.F., Breiman R.F., Fields B.S., Herbert M., Inverso J., and Knirsch C. Azithromycin in the treatment of Legionella pneumonia requiring hospitalization Clin Infect Dis 37 2003 1475 1480
11. Kenny G.E., and Cartwright F.D. Susceptibilities of Mycoplasma hominis, Mycoplasma pneumoniae, and Ureaplasma urealyticum to GAR-936, dalfopristin, dirithromycin, evernimicin, gatifloxacin, linezolid, moxifloxacin, quinupristin-dalfopristin, and telithromycin compared to their susceptibilities to reference macrolides, tetracyclines, and quinolones Antimicrob Agents Chemother 45 2001 2604 2608
12. Roblin P.M., Reznik T., and Hammerschlag M.R. In vitro activity of garenoxacin against recent clinical isolates of Chlamydia pneumoniae Int J Antimicrob Agents 21 2003 578 580
13. Gomes-Lus R., Adrian F., del Campo R., Gomez-Lus P., Sanchez S., and Garcia C. Comparative in vitro bacteriostatic and bactericidal activity of trovafloxacin, levofloxacin and moxifloxacin against clinical and environmental isolates of Legionella spp. Int J Antimicrob Agents 18 2001 49 54
14. Dubois J., and St Pierre C. In vitro activity of gatifloxacin, compared with ciprofloxacin, clarithromycin, erythromycin, and rifampin, against Legionella species Diagn Microbiol Infect Dis 33 1999 261 265
15. Eliopoulos G.M. Quinolone resistance mechanisms in Pneumococci Clin Infect Dis 38 Suppl 4 2004 350 356
16. Chalumeau M., Tonnelier S., d'Arthis P., Treluyer J.M., Gendrel D., and Breart G. Fluoroquinolone safety in pediatric patients: a prospective, multicenter, comparative cohorte study in France Pediatrics 111 2003 e714 3719
17. Dagan R., Arguedas A., and Schaad U.B. Potential role of fluoroquinolone therapy in childhood otitis media Ped Infect Dis J 23 2004 390 398
18. Zhanel G.G., Walters M., Noreddin A., Vercaigne L.M., Wierzbowski A., and Embil J.M. The Ketolides: a critical review Drugs 62 2002 1771 1804
19. Miyashita N., Fukano H., Yoshida K., Niki Y., and Matsushima T. In vitro activity of cethromycin, a novel antibacterial ketolide, against Chlamydia pneumoniae J Antimicrob Chemother 52 2003 497 499
20. Abstract 2159 Sens K., Mietzner S., and Sagnimeni A. Activity of new quinolones, macrolide, and ketolide against 100 strains of Legionella species using broth dilution and intracellular susceptibility testing methods 40th ICAAC Toronto, Ontario, Canada September 17-20, 2000
21. Shackcloth J., Williams L., and Farrell D.J. Streptococcus pneumoniae and Streptococcus pyogenes isolated from a paediatric population in Great Britain and Ireland: the in vitro activity of telithromycin versus comparators J Infect 48 2004 229 235
22. Felmingham D., Reinert R.R., Hirakata Y., and Rodloff A. Increasing prevalence of antimicrobial resistance among isolates of Streptococcus pneumoniae from the PROTEKT surveillance study, andcomparative in vitro activity of the ketolide, telithromycin J Antimicrob Chemother 50 suppl. S1 2002 25 37
23. Hagberg L., Carbon C., van Rensburg D.J., Fogarty C., Dunbar L., and Pullman J. Telithromycin in the treatment of community-acquired pneumonia: a pooled analysis Respir Med 97 2003 625 633